ALSO NOTED: NBTY buys Solgar; Ind-Swift expanding; Shire gets new Adderall letter; and much more...

> NBTY is buying Wyeth's Solgar Vitamin and Herb for $115 million. Story

> India's Ind-Swift is expanding its manufacturing operations. Article

> The UK's Shire Pharmaceuticals has received a second letter from Teva covering an amendment to its ANDA on a generic version of Adderall XR. Story

> Toronto-based Lorus says its cancer drug Virulizin has been granted orphan drug status in the European Union. Release

> Evotec has received its first milestone from its partnership with Boehringer Ingelheim. Release

> San Diego-based TorreyPines Therapeutics has filed an IND for NGX267, the first of several compounds in the company's product pipeline that are designed to treat Alzheimer's disease. Release

And Finally... The New York Times examines the widespread incidence of shingles and breakthrough research on a vaccine that could cure it for a majority of patients. Story

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.